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Objective: To describe the clinical and laboratory presentation of hemophagocytic
lymphohistiocytosis in children treated at a referral institution.
Methods: A retrospective descriptive study was carried out of seven children diagnosed with
hemophagocytic lymphohistiocytosis between 2010 and 2012. The criteria for diagnosis
were those proposed by the Histiocyte Society. When indicated, immunochemotherapy was
prescribed according to the HLH94 and HLH2004 protocols of the Histiocyte Society.
Results: The patients’ ages at diagnosis ranged from one month to nine years. All patients
had splenomegaly, fever, anemia, thrombocytopenia, hyperferritinemia and hypertriglyc-
eridemia. Bone marrow hemophagocytosis was detected in six patients. In six cases,
infectious diseases triggered the syndrome. In two cases, associated with visceral leishman-
iasis,  remission was achieved after treatment of the underlying infection. Three patients,
who  had Epstein–Barr-related hemophagocytic lymphohistiocytosis, required treatment
with immunochemotherapy. They are alive and in remission; one patient had symp-
toms of juvenile rheumatoid arthritis and another, who was suspected of having primary
hemophagocytic lymphohistiocytosis, entered into remission after bone marrow transplan-
tation. Two deaths (28.6%) occurred in patients with suspected primary hemophagocytic
lymphohistiocytosis; one whose clinical picture was triggered by cytomegalovirus infection
did not respond to immunochemotherapy and the other died before any speciﬁc treatment
was  provided.
Conclusion: As reported before, hemophagocytic lymphohistiocytosis has a multifaceted
presentation with nonspeciﬁc signs and symptoms. In secondary forms, remission may
be  achieved by treating the underlying disease. In the primary forms, remission may be
achieved with immunochemotherapy, but bone marrow transplantation is required for cure.o Bra©  2014 Associac¸ã∗ Corresponding author at: Universidade Federal de Minas Gerais (UFM
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Introduction
Hemophagocytic lymphohistiocytosis (HLH) is an immune
hyperactivation syndrome characterized by clinical signs and
symptoms of severe uncontrolled inﬂammation.1
Diagnosis is based on combined clinical, laboratory,
genetic, and morphological criteria. According to the Histio-
cyte Society,2 in the absence of family history or of speciﬁc
genetic tests, ﬁve out of eight criteria must be present in order
to establish a diagnosis and initiate treatment (Table 1).
Common ﬁndings in HLH include persistent fever, hep-
atosplenomegaly, cytopenia, decreased activity of cytotoxic
T lymphocytes and natural killer cells (NK), as well as
widespread accumulation of lymphocytes and macrophages
that carry out hemophagocytosis.3
HLH is included in the differential diagnosis of a number
of diseases commonly found in children, such as autoim-
mune diseases, primary immunodeﬁciencies, malignancies,
and infectious diseases.3
There are two main forms, primary or familial HLH and sec-
ondary HLH. Secondary HLH can be associated with infections,
autoimmune disorders or malignancies. Despite attempts to
differentiate between primary and secondary forms of HLH,
their clinical features are very similar.4,5
Remission may be achieved in primary HLH with
immunochemotherapy and in cases of secondary HLH by
treating the underlying disease.6–8 However, all patients with
the familial form of HLH relapsed or died until treatment using
allogeneic bone marrow transplantation (BMT) started to be
used.2,6
Given its rarity and the scarcity of data in the Brazilian lit-
erature, this retrospective study was carried out to describe
the clinical and laboratory presentation of HLH in children
followed at the Hematology Service of the Hospital das Clini-
cas, Universidade Federal de Minas Gerais (HC-UFMG) between
January 2010 and July 2012.
Table 1 – Criteria for the diagnosis of hemophagocytic
lymphohistiocytosis.
A. Molecular diagnosis compatible with hemophagocytic
lymphohistiocytosis
OR
B. At least ﬁve out of the eight following criteria:
1. Fever
2. Splenomegaly
3. Cytopenias (two or more lineages)
- Hemoglobin <9 g/dL or <10 g/dL in newborn babies
- Platelets <100 × 109/L
- Neutrophils <1.0 × 109/L
4. Hypertriglyceridemia (>265 mg/dL) or hypoﬁbrinogenemia
(<150 mg/dL)
5. Hemophagocytosis in bone marrow, spleen, lymph nodes or
liver without any evidence of malignancy
6. Decreased or absent activity of natural killer cells
7. Serum ferritin >500 g/L
8. Increased soluble CD25 (>2400 U/mL)
Modiﬁed from Henter et al.2 2 0 1 4;3  6(6):437–441
The study was approved by the Institution’s Research Ethics
Committee (protocol no. 05683012.9.0000.5149), and patients
and guardians were asked to sign informed consent forms.
Case  report
Seven children were included. Age at diagnosis ranged from
one month to nine years, with a median of 13 months. All
patients presented with splenomegaly and fever. Other clin-
ical manifestations are shown in Table 2. Only one case (#7)
had a family history suggesting HLH.
All children had anemia, thrombocytopenia, hypertriglyc-
eridemia, and hyperferritinemia at the time of diagnosis.
Hypoﬁbrinogenemia was observed in six cases (85.7%).
Hemophagocytosis features were visible in the bone marrows
of six patients (85.7%) at diagnosis (Table 2). Lumbar punc-
ture with cerebrospinal ﬂuid (CSF) analysis was performed in
two cases; both had pleocytosis. Cranial computed tomogra-
phy was performed in one patient (#4) which revealed diffuse
cortical atrophy.
The estimated time between the onset of symptoms and
HLH diagnosis ranged from 10 to 60 days (median of 50 days).
The initial investigation showed that in six cases (85.7%)
the clinical picture was prompted by infectious diseases, two
of which (33.3%) were secondary to visceral leishmaniasis,
three (50%) after infections with Epstein–Barr virus (EBV) and
one (16.7%) triggered by cytomegalovirus (Table 2).
Four cases were considered secondary forms: two had vis-
ceral leishmaniasis (#1 and #3) and entered into remission
after the infection was treated with liposomal amphotericin
B but without speciﬁc therapy for HLH. The initial clinical pic-
ture of the patient with positive serology (IgM) for EBV was
severe;  he received induction therapy following the HLH94
protocol, and entered into remission after eight weeks (#5).
The last patient (#6) had a prior diagnosis of juvenile rheuma-
toid arthritis and developed HLH secondary to the underlying
disease (macrophage activation syndrome) triggered by EBV
infection. The child received induction therapy following the
HLH2004 protocol and entered into remission after eight
weeks. The secondary form cases are currently being followed
as outpatients and continue in remission.
After a retrospective review, the other three cases were con-
sidered likely to have been primary forms of HLH. Data that
contributed to this suspicion were: age at diagnosis (all were
infants), no response to immunochemotherapy (in two  cases),
and in the third case, history of siblings dying with similar
clinical presentations.
Two patients (#2 and #4) received immunochemotherapy
(Histiocyte Society HLH2004 and HLH94 protocols)2,7,8 and
failed to achieve remission after the induction and main-
tenance phases. The ﬁrst patient (#2) underwent unrelated
allogeneic bone marrow transplantation and responded well.
He is currently being followed in the outpatient clinic. After
a seven-month follow-up, the second patient (#4) died from
severe sepsis of a pulmonary focus with active disease.The third patient (#7) aged one month and with a family
history of death of siblings from rapid infectious complica-
tions, died 48 h after admission, presenting with severe sepsis
of an unknown etiologic agent before there was enough time
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Table 2 – Clinical and laboratorial characteristics of seven children with hemophagocytic lymphohistiocytosis (HLH).
# Gender Age at
diagnosis
Enlarged
lymph nodes
Cutaneous
rash
Jaundice Fibrinogen
(mg/dL)
Hemophagocytosis
in  bone marrow
Spinal ﬂuid
exam
Infections and
associated diseases
Type of immunochemother-
apy/present clinical
status
1 F 5 months No No Yes 89 No ND Visceral leishmaniasis ND/Alive in remission
2 M 13 months No No No >400 Yes Pleocytosis Epstein–Barr virus HLH 2004/Bone marrow
transplantation in July 2012;
alive in remission
3 M 5 months No No No 97 Yes ND Visceral leishmaniasis ND/Alive in remission
4 M 16 months Yes Yes Yes 131 Yes ND Cytomegalovirus HLH 1994/No remission.
Death after sepsis
5 M 3 years Yes No Yes 59 Yes ND Epstein–Barr virus HLH 1994/Alive in remission
6 F 9 years No Yes Yes 94 Yes Pleocytosis Epstein–Barr
virus/Juvenile
Rheumatoid Arthritis
HLH 2004/Alive in remission
7 M 1 month No No No 35 Yes ND None proven ND/Death after 48 h from
hospital admission
F: female; M: male; ND: not done.
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to start speciﬁc treatment. Results from the autopsy suggested
HLH.
Mortality among patients in the study was 28.6% (2/7) and
both deaths occurred in patients suspected of having primary
HLH.
Discussion
HLH has multifaceted presentations with nonspeciﬁc signs
and symptoms that are found in other clinical conditions. In
the present study the most frequent clinical and laboratory
ﬁndings at diagnosis were prolonged fever, splenomegaly, and
cytopenias, particularly anemia and thrombocytopenia, as has
already been described in the literature.3
Hemophagocytosis, the phenomenon that lends its name
to the nosological entity, is not a prerequisite for the clini-
cal diagnosis of HLH.6 This phenomenon was observable at
some point during the follow-up in all but one case of this
series. Nevertheless, absence of hemophagocytosis should not
delay the diagnosis when the initial clinical picture fulﬁlls
the other criteria.3 This morphological phenomenon can also
be induced by other events such as blood transfusion, infec-
tion, autoimmune diseases, and some types of bone marrow
failure.6
Despite the limited access to more  complex laboratory
tests, common to many  institutions where molecular genetic
studies and assessment of NK cell activity and soluble CD256
are not available, HLH diagnosis was possible in the seven
reported cases because each fulﬁlled at least ﬁve of the eight
criteria described by the Histiocyte Society.2 The absence of
molecular studies, however, prevented conﬁrmation of the
diagnosis of primary HLH cases, essential for predicting the
risk of recurrence and for deﬁning disease predisposition in
asymptomatic family members.6
In this case series, only three patients underwent investiga-
tion for changes in the central nervous system (CNS). In two
of these cases, the CSF was examined, and pleocytosis was
detected in both, with atypical cells present in one. Neuro-
logical abnormalities are a prominent feature of this disease.
CNS involvement can cause severe and irreversible damage.
It is recommended that all patients should be submitted to
neurological evaluations with lumbar puncture even when
asymptomatic.6,9
Familial HLH is considered an autosomal recessive genetic
disorder with an estimated prevalence of 1/50,000 live births.
Approximately 70–80% of patients with familial HLH have
symptoms in the ﬁrst year of life.3 Although cases with docu-
mented genetic defects are, by deﬁnition, primary, infectious
processes appear as the trigger in the majority of these chil-
dren. Because it is a recessive disorder, negative family history
is common and results in such cases are wrongly deﬁned as
secondary, especially when initial treatment induces satisfac-
tory clinical remission.5 Thus, the use of the terms primary
and secondary HLH is not ideal.
In the present study, patients with suspected familial HLH
manifested symptoms within the ﬁrst two years of life. In two
cases, a related infectious disease was identiﬁed. The patient
whose diagnosis was established in the second month of life
was the most severe case and rapidly progressed to death. 2 0 1 4;3  6(6):437–441
As described in the literature, the younger the patient is at
diagnosis, the greater the severity of the presentation.2,6,8
Six cases were related to infections, which also concurs
with descriptions in several reviews on the topic.2,4,6,7 Accord-
ing to the Histiocyte Society study HLH94 and many  other
studies, the most common infectious trigger is the EBV; in
these cases, the initial clinical picture is typically severe.6,7,10
However, there are reports that clinical presentation of HLH
secondary to EBV infection is very variable, ranging from spon-
taneously resolved inﬂammation to extremely severe cases
that require immunochemotherapy10 followed by stem cell
transplantation.2 Among the patients in this sample who  had
EBV-related HLH, all had very severe initial clinical presenta-
tions and required immunochemotherapy to control signs and
symptoms.
In this series, two cases were associated with visceral leish-
maniasis. Both achieved HLH remission after the underlying
infection was treated and required no anti-inﬂammatory or
cytotoxic therapies, also in agreement with the literature. It is
important to note, however, that without treating the under-
lying infection, the mortality rate is very high.3
Macrophage activation syndrome occurred in one patient
previously diagnosed with juvenile rheumatoid arthritis, the
autoimmune disease most commonly associated with HLH.
The patient initially presented with severe hepatitis and coag-
ulopathy, very common ﬁndings in this speciﬁc group of
patients.3
The immediate goal of treatment of patients with HLH is
to suppress the hyperinﬂammation, responsible for the symp-
toms that put the patient’s life at risk. Thus, chemotherapeutic
and/or immunosuppressive agents such as corticosteroids,
cyclosporin, and immunoglobulin are used. In familial HLH,
the ultimate goal should be stem cell transplantation to substi-
tute the defective immune system with properly functioning
effector cells. Without treatment, uncontrolled hyperinﬂam-
mation leads to persistent neutropenia and death from
repeated fungal and bacterial infections or multiple organ
failure.4,8
A retrospective review of this series revealed that com-
plete response after immunochemotherapeutic treatment
was  achieved only in patients with a diagnosis of secondary
HLH. Although effective in prolonging the survival of patients
with familial HLH, it is known that immunochemotherapy
alone cannot cure this form of the disease.6
The mortality rate in our study was 28.6%, lower than the
death rate described by the Histiocyte Society, which is around
50%.2,6,7 The number of cases in our series, however, is very
small. If we  consider that all deaths occurred in patients with
primary HLH and of those, only the one who  underwent BMT
is alive, the data from this study is in agreement with the lit-
erature, which gives a 100% mortality rate for patients with
primary HLH who are not submitted to BMT.3,6,10
Despite the small sample size, test limitations, and the
retrospective nature of this study, all of which are factors
that prevent more  deﬁnitive conclusions, the cases presented
here demonstrate the importance of raising awareness about
HLH among professionals involved in the care of pediatric
patients. Access to diagnostic procedures that allow a more
deﬁnite diagnosis of suspected cases of familial HLH are evi-
dently needed, both for the patient and for conducting family
er. 2 0
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ounseling. We  should emphasize the need for prospective
nd cooperative studies in order to enhance understanding
bout HLH in Brazil, so as to improve its clinical management.
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